The drug industry is lobbying for potential tariffs to be implemented gradually instead of immediately being imposed at a 25% rate.

Ideaya Biosciences, Inc.'s stock faces pressure from macroeconomic shifts and FDA policies, but remains a buy for savvy ...

It's only a week since Rachel Reeves unveiled her Spring Statement but her plan to balance the nation's books looks set to ...

Siemens partners with Miko Pharma to develop cutting-edge pharmaceutical manufacturing facilities in Ghana. The agreement ...

Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt ...

President Donald Trump is expected to announce sweeping tariffs on “all countries" affecting many industries, the likes of ...

With the recently announced layoffs of 3,500 FDA staffers and exits of branch directors Patrizia Cavazzoni and Peter Marks, ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

We purchased shares of Icon in March 2024 for ~$323.00 per share. Why did we sell our ICLR position and move on? Click here ...

Polish medical diagnostics group Diagnostyka said on Wednesday it had acquired 51% stake in Eurodiagnostic, a company that manages mobile computed tomography (CT), magnetic resonance (MR) and X-ray ...

Europe’s pharmaceutical sector is bracing for the potential impact of U.S. tariffs as hopes of an industry-wide exemption by ...